Asia Pacific Central Nervous System Therapeutic Market Size & Outlook

Name: Asia Pacific Central Nervous System Therapeutic Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The central nervous system therapeutic market in Asia Pacific is expected to reach a projected revenue of US$ 60,215.3 million by 2033. A compound annual growth rate of 10.1% is expected of Asia Pacific central nervous system therapeutic market from 2026 to 2033.

Pharmaceuticals
- Neurology Drugs
  - Central Nervous System Therapeutic Market Outlook

Asia Pacific central nervous system therapeutic disease outlook (Revenue, USD million, 2021-2033)
- Neurovascular Diseases
- CNS Trauma
- Mental Health
  - Anxiety Disorders
  - Epilepsy
  - Mood Disorders
  - Psychotic Disorders
  - Others
- Neurodegenerative Diseases
  - Alzheimer’s Disease
  - Parkinsosn’s Disease
  - Multiple Sclerosis
  - Huntington’s Disease
  - Amytrophic Lateral Sclerosis
  - Others
- Infectious Diseases
- CNS Cancer
- Others
Asia Pacific central nervous system therapeutic drug class outlook (Revenue, USD million, 2021-2033)
- Antidepressants
- Antipsychotics
- Antiepileptics (AEDs)
- Dopaminergic Agents
- Neuroprotective Agents
- Immunomodulators
- Others
Asia Pacific central nervous system therapeutic distribution channel outlook (Revenue, USD million, 2021-2033)
- Hospital Pharmacy
- Retail Pharmacy
- Others

Asia Pacific Central Nervous System Therapeutic Market Size & Outlook

Data Tree

Sign up - it's easy, and free!